| Autor: |
Shaffer BR; Department of Dermatology, Wake Forest University School of Medicine, Winston-Salem, NC, USA., Zaino M; Department of Dermatology, Wake Forest University School of Medicine, Winston-Salem, NC, USA., Prajapati S; Department of Dermatology, Wake Forest University School of Medicine, Winston-Salem, NC, USA., Chandy RJ; Department of Dermatology, Wake Forest University School of Medicine, Winston-Salem, NC, USA., Feldman SR; Department of Dermatology, Wake Forest University School of Medicine, Winston-Salem, NC, USA.; Department of Pathology, Wake Forest University School of Medicine, Winston-Salem, NC, USA.; Department of Social Sciences and Health Policy, Wake Forest University School of Medicine, Winston-Salem, NC, USA. |
| Abstrakt: |
Competing Interests: Declaration of Conflicting InterestsThe author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: Feldman has received research, speaking, and/or consulting support from AbbVie, Accordant, Almirall, Alvotech, Amgen, Arcutis, Arena, Argenx, Biocon, Boehringer Ingelheim, Bristol-Myers Squibb, Dermavant, Eli Lilly and Company, Eurofins, Forte, Galderma, Helsinn, Janssen, Leo Pharma, Micreos, Mylan, Novartis, Ono, Ortho Dermatology, Pfizer, Regeneron, Samsung, Sanofi, Sun Pharma, UCB, Verrica, Voluntis, and vTv Therapeutics. He is founder and part owner of Causa Research and holds stock in Sensal Health. Shaffer, Zaino, Prajapati, and Chandy have no conflicts to disclose. |
